SPSaranya Palaniswamy

Saranya Palaniswamy

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Saranya Palaniswamy has a total of 7 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Dengue-associated Miller Fisher syndrome: a para-infectious presentation

    by R. Selva Balaji, Vishnu Prasath, Saranya Palaniswamy, D. Kanimozhi, R. Kannan

    Background. Miller Fisher syndrome (MFS), a rare Guillain-Barré syndrome (GBS) variant, usually presents with classical triad of ophthalmoplegia, ataxia, and areflexia. It is typically post-infectious and immune mediated; para-infectious presentations associated with dengue virus are uncommon. Case presentation. We report a 65-year-old man with type 2 diabetes mellitus who presented with a five-day history of high-grade fever and a two-day history of diplopia, bilateral ptosis, and gait unsteadiness. Examination revealed ophthalmoplegia, areflexia, and ataxia. Laboratory evaluation showed severe thrombocytopenia. Dengue NS1 antigen and IgM antibody were positive. MRI brain was normal, and nerve conduction studies demonstrated motor axonal polyneuropathy. Anti-GQ1b antibody was negative. The patient was treated with IVIG and supportive care, resulting in complete neurological recovery. Conclusion. Acute dengue infection associated MFS is rare. This case highlights that neurological manifestations may occur during the active phase of dengue, even in the absence of anti-GQ1b antibodies, suggesting alternative pathogenic mechanisms. Early recognition of the classical clinical triad and timely immunotherapy can lead to favorable neurological outcomes.

  • Open Access

    Clinical and Antimicrobial Profile of Acinetobacter Species in Critical Care Setting- An Emerging Nosocomial Bug

    by Fathima S Nilofar, I Mariraj, Saranya Palanisamy, Babu R Nitesh

    Background: The increasing prevalence of multidrug-resistant bacterial infections, particularly within healthcare-associated settings, poses a global public health threat. Among these pathogens, Acinetobacter species, notably Acinetobacter baumannii, have gained recognition as opportunistic nosocomial pathogens with a concerning propensity for antimicrobial resistance. Understanding their clinical and antimicrobial profile is crucial for addressing the challenges posed by these infections.Objectives: To assess the prevalence of Acinetobacter species in distinct clinical samples.To analyze Acinetobacter species' clinical profiles and patterns of antibiotic sensitivity using a range of clinical samples.Materials and Methods: A cross-sectional study was conducted in a tertiary care hospital in South India, approved by the Institutional Ethics Committee. Patients with confirmed Acinetobacter infections were included, and clinical samples were collected from the critical care unit. Demographics, comorbidities, clinical presentations, and outcomes were recorded. Laboratory processing included standard protocols for sample analysis, with confirmation through advanced methods such as PCR.Results: Out of 82 participants, 48.78% showed positive cultures for Acinetobacter species. Prevalence varied by sample type, with urine samples exhibiting the highest positivity (50%). Clinical analysis of 40 infected patients revealed a mean age of 43.72 ± 17.34 years. Musculoskeletal symptoms (17.5%) and obstetric complications (17.5%) were prominent clinical presentations. Antibiotic sensitivity analysis demonstrated that 51% of isolates were multidrug-resistant, with high resistance to key antibiotics. Commonly resistant antibiotics included Cefepime, Piperacillin, Levofloxacin, Imipenem, Meropenem, and Amikacin.Conclusion: This study adds to the growing understanding of Acinetobacter infections, emphasizing the need for awareness, infection control, and judicious antibiotic use. The multidisciplinary clinical presentations and high resistance rates underscore the complexity of managing Acinetobacter infections, requiring a holistic approach in healthcare settings. The findings inform strategies for infection prevention, surveillance, and therapeutic approaches in the global effort to combat antimicrobial resistance